Added benefit of Bayer's Eylea again not proven, says IQWiG

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) reviewed aflibercept, drug major Bayer’s (BAYN: DE) ophthalmic drug Eylea, returning a negative opinion.

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether Eylea offers an added benefit over the appropriate comparator therapy in visual impairment due to macular edema following occlusion of the central retinal vein.

An added benefit could not be derived from the dossier because in the studies cited by the drug manufacturer, both aflibercept and the comparator therapy were not used in accordance with their approvals, the IQWiG stated.